Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections
Abstract
High occurrence of penicillin-resistant and multidrug-resistant Streptococcus pneumoniae and reports of resistance with Haemophilus influenzae and Moraxella catarrhalis are influencing the empiric treatment of community-acquired respiratory infections and allowing the new fluoroquinolones to serve as important treatment alternatives. Recent analysis of the pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin) have shown high bioavailability (> or = 70%) and long serum half-lives (> or = 7 h), allowing for once-daily dosing. They concentrate in respiratory tract tissues and fluids at levels that exceed serum concentrations. Concentration-dependant killing is evident and the pharmacodynamic parameters that best correlate with bacteriological eradication, clinical efficacy and minimization of resistance have now been identified. The new fluoroquinolones display excellent pharmacokinetic and pharmacodynamic properties against community-acquired respiratory pathogens, making them ideal agents for the empirical treatment of community-acquired respiratory infections.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.